IRCT20200506047323N3
Recruiting
Phase 3
Evaluation of the efficacy and safety of Favipiravir and Interferon beta compared to Lopinavir/Ritonavir and Interferon beta in patients with COVID-19
Bandare-abbas University of Medical Sciences0 sites60 target enrollmentTBD
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Bandare-abbas University of Medical Sciences
- Enrollment
- 60
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \=18 years
- •Positive polymerase chain reaction (PCR) test for COVID\-19
- •Primary clinical symptoms
- •Hospitalized
- •Signing informed consent and willingness of study participant to accept randomization to any assigned treatment arm
Exclusion Criteria
- •Underlying diseases, including chronic hepatitis, cirrhosis, cholestatic liver diseases, cholecystitis, and peptic ulcers
- •Acute and chronic renal failure
- •Peptic ulcers
- •History of allergy to studied drugs
- •Pregnancy and breastfeeding
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
The evaluation of efficacy of Favipiravir in patients with mild to moderate COVID-19IRCT20201005048936N1Dr. Abidi pharmacutical Co.126
Recruiting
Phase 3
Evaluation the effects of Favipiravir in COVID-19 patientsCOVID-19 pneumonia.COVID-19, virus identifiedU07.1IRCT20151227025726N14Shahid Beheshti University of Medical Sciences84
Recruiting
Phase 2
Effectiveness of favipiravir in comparison with Tenofovir Alafenamid in patients with COVID-19COVID-19.COVID-19U07.1IRCT20150808023559N23Ardabil University of Medical Sciences100
Completed
Not Applicable
Investigation on the efficacy and safety of favipiravir in patients who are infected or strongly suspected of being infected with Ebola virusEbola virus diseaseJPRN-UMIN000016101ational Center for Global Health and Medicine5
Recruiting
Phase 3
Evaluation of the efficiency and safety of favipiravir + hydroxychloroquine drug regimen in comparison with hydroxychloroquine in hospitalized patients with covid-19IRCT20200428047228N1Quality Improvement of Intensive Care Research Center- Shahid Beheshti University50